Affiliation:
1. University of California, Irvine
2. UCI
3. Lawrence Livermore National Laboratory
Abstract
Abstract
To determine the safety and protective efficacy of a C. muridarum MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide ISA 720 VG (70%, 50%, 30% and 10%), BALB/c mice were immunized twice intramuscularly. Local reactogenicity was significant for vaccines formulated with 70% and 50% Montanide but not in mice receiving 30% and 10% Montanide. Robust humoral and cell mediated memory immune responses were elicited by the 70%, 50% and 30% Montanide formulations. Mice were challenged intranasally with C. muridarum and, at day 10 post-challenge, mice were euthanized. Based on changes in body weight, lung’s weight and number of IFU recovered, mice vaccinated with the 70%, 50% and 30% Montanide formulations were significantly protected, but not mice receiving 10% Montanide. To conclude, we recommend the 30% Montanide concentration to be tested in humans and animal models to determine its safety and efficacy, in comparison to the 70% Montanide concentration currently used. The 30% Montanide formulation will significantly facilitate licensing for human use.
Publisher
Research Square Platform LLC
Reference22 articles.
1. CDC. (ed Division of STD prevention) 1-168 (U.S. Department of Health and Human Services. Atlanta., 2021).
2. Schachter, J. & Dawson, C. R. Human chlamydial infections. (PSG Pub. Co., 1978).
3. Respiratory-tract colonization and a distinctive pneumonia syndrome in infants infected with Chlamydia trachomatis;Beem MO;N Engl J Med,1977
4. Chlamydia trachomatis Genital Infections;O'Connell CM;Microb Cell,2016
5. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1;Plummer FA;J Infect Dis,1991